Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Liabilities: 2015-2024

Historic Total Liabilities for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $126.0 million.

  • Seres Therapeutics' Total Liabilities fell 35.55% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 35.55%. This contributed to the annual value of $126.0 million for FY2024, which is 68.76% down from last year.
  • Latest data reveals that Seres Therapeutics reported Total Liabilities of $126.0 million as of FY2024, which was down 68.76% from $403.5 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Total Liabilities registered a high of $403.5 million during FY2023, and its lowest value of $126.0 million during FY2024.
  • For the 3-year period, Seres Therapeutics' Total Liabilities averaged around $289.2 million, with its median value being $338.0 million (2022).
  • As far as peak fluctuations go, Seres Therapeutics' Total Liabilities spiked by 51.33% in 2022, and later plummeted by 68.76% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Total Liabilities stood at $168.2 million in 2020, then skyrocketed by 32.80% to $223.4 million in 2021, then surged by 51.33% to $338.0 million in 2022, then increased by 19.37% to $403.5 million in 2023, then crashed by 68.76% to $126.0 million in 2024.